Patents by Inventor Irina Nikolaevna Kadiyala

Irina Nikolaevna Kadiyala has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220324832
    Abstract: The present invention provides crystalline forms of a compound of formula (I): Also provided are pharmaceutical compositions that include the provided crystalline forms and methods of using the provided crystalline forms and pharmaceutical compositions for the treatment of cancer.
    Type: Application
    Filed: June 16, 2022
    Publication date: October 13, 2022
    Inventors: Gary DeCrescenzo, Dean Welsch, Petinka I. Vlahova, Stephan X.M. Boerrigter, Alexander Aronov, Ali Keshavarz-Shokri, Alexander N. Scangas, Kathy Stavropoulos, Benjamin Littler, Irina Nikolaevna Kadiyala, Rossitza Gueorguieva Alargova
  • Patent number: 11390600
    Abstract: The present invention provides crystalline forms of a compound of formula (I): Also provided are pharmaceutical compositions that include the provided crystalline forms and methods of using the provided crystalline forms and pharmaceutical compositions for the treatment of cancer.
    Type: Grant
    Filed: July 7, 2020
    Date of Patent: July 19, 2022
    Assignees: Biomed Valley Discoveries, Inc., Vertex Pharmaceuticals Incorporated
    Inventors: Gary DeCrescenzo, Dean Welsch, Petinka I. Vlahova, Stephan X. M. Boerrigter, Alexander Aronov, Ali Keshavarz-Shokri, Alexander N. Scangas, Kathy Stavropoulos, Benjamin Littler, Irina Nikolaevna Kadiyala, Rossitza Gueorguieva Alargova
  • Publication number: 20220031679
    Abstract: A pharmaceutical composition comprising Compound 1, (3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid), and at least one excipient selected from: a filler, a diluent, a disintegrant, a surfactant, a binder, a glidant and a lubricant, the composition being suitable for oral administration to a patient in need thereof to treat a CFTR mediated disease such as Cystic Fibrosis. Methods for treating a patient in need thereof include administering an oral pharmaceutical formulation of Compound 1 to the patient.
    Type: Application
    Filed: May 28, 2021
    Publication date: February 3, 2022
    Applicant: Vertex Pharmaceuticals Incorporated
    Inventors: Marinus Jacobus VERWIJS, Rossitza Gueorguieva ALARGOVA, Ritu Rohit KAUSHIK, Irina Nikolaevna KADIYALA, Christopher YOUNG
  • Patent number: 11052075
    Abstract: A pharmaceutical composition comprising Compound 1, (3-(6-(1-(2,2-difluorobenzo [d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid), and at least one excipient selected from: a filler, a diluent, a disintegrant, a surfactant, a binder, a glidant and a lubricant, the composition being suitable for oral administration to a patient in need thereof to treat a CFTR mediated disease such as Cystic Fibrosis. Methods for treating a patient in need thereof include administering an oral pharmaceutical formulation of Compound 1 to the patient.
    Type: Grant
    Filed: August 2, 2019
    Date of Patent: July 6, 2021
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Marinus Jacobus Verwijs, Rossitza Gueorguieva Alargova, Ritu Rohit Kaushik, Irina Nikolaevna Kadiyala, Christopher Young
  • Publication number: 20200339531
    Abstract: The present invention provides crystalline forms of a compound of formula (I): Also provided are pharmaceutical compositions that include the provided crystalline forms and methods of using the provided crystalline forms and pharmaceutical compositions for the treatment of cancer.
    Type: Application
    Filed: July 7, 2020
    Publication date: October 29, 2020
    Inventors: Gary DeCrescenzo, Dean Welsch, Petinka I. Vlahova, Stephan X.M. Boerrigter, Alexander Aronov, Ali Keshavarz-Shokri, Alexander N. Scangas, Kathy Stavropoulos, Benjamin Littler, Irina Nikolaevna Kadiyala, Rossitza Gueorguieva Alargova
  • Patent number: 10738027
    Abstract: The present invention provides crystalline forms of a compound of formula (I): Also provided are pharmaceutical compositions that include the provided crystalline forms and methods of using the provided crystalline forms and pharmaceutical compositions for the treatment of cancer.
    Type: Grant
    Filed: December 20, 2018
    Date of Patent: August 11, 2020
    Assignees: Biomed Valley Discoveries, Inc., Vertex Pharmaceuticals Incorporated
    Inventors: Gary DeCrescenzo, Dean Welsch, Petinka I. Vlahova, Stephan X. M. Boerrigter, Alexander Aronov, Ali Keshavarz-Shokri, Alexander N. Scangas, Kathy Stavropoulos, Benjamin Littler, Irina Nikolaevna Kadiyala, Rossitza Gueorguieva Alargova
  • Patent number: 10716789
    Abstract: The present invention relates to compositions and co-crystals each comprising a compound of formula I having the structure: wherein each of R1 and R2 is H or 2H and a co-crystal former selected from adipic acid, citric acid, fumaric acid, maleic acid, succinic acid, or benzoic acid. Also within the scope of this invention are methods of making and using the same.
    Type: Grant
    Filed: July 18, 2018
    Date of Patent: July 21, 2020
    Assignee: VERTEX PHARMACEUTICALS INCORPORATED
    Inventors: Kwame Wiredu Nti-Addae, Simon Adam O'Neil, Yuegang Zhang, Michael P. Waldo, Praveen Mudunuri, Bin Song, John Gregg Van Alsten, Mark Strohmeier, Kathy Stavropoulos, Irina Nikolaevna Kadiyala, Mettachit Navamal
  • Publication number: 20200197380
    Abstract: A pharmaceutical composition comprising Compound 1, (3-(6-(1-(2,2-difluorobenzo [d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid), and at least one excipient selected from: a filler, a diluent, a disintegrant, a surfactant, a binder, a glidant and a lubricant, the composition being suitable for oral administration to a patient in need thereof to treat a CFTR mediated disease such as Cystic Fibrosis. Methods for treating a patient in need thereof include administering an oral pharmaceutical formulation of Compound 1 to the patient.
    Type: Application
    Filed: August 2, 2019
    Publication date: June 25, 2020
    Applicant: Vertex Pharmaceuticals Incorporated
    Inventors: Marinus Jacobus Verwijs, Rossitza Gueorguieva Alargova, Ritu Rohit Kaushik, Irina Nikolaevna Kadiyala, Christopher Young
  • Publication number: 20190127348
    Abstract: The present invention provides crystalline forms of a compound of formula (I): Also provided are pharmaceutical compositions that include the provided crystalline forms and methods of using the provided crystalline forms and pharmaceutical compositions for the treatment of cancer.
    Type: Application
    Filed: December 20, 2018
    Publication date: May 2, 2019
    Inventors: Gary DeCrescenzo, Dean Welsch, Petinka I. Vlahova, Stephan X.M. Boerrigter, Alexander Aronov, Ali Keshavarz-Shokri, Alexander N. Scangas, Kathy Stavropoulos, Benjamin Littler, Irina Nikolaevna Kadiyala, Rossitza Gueorguieva Alargova
  • Publication number: 20190070155
    Abstract: A pharmaceutical composition comprising Compound 1, (3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid), and at least one excipient selected from: a filler, a diluent, a disintegrant, a surfactant, a binder, a glidant and a lubricant, the composition being suitable for oral administration to a patient in need thereof to treat a CFTR mediated disease such as Cystic Fibrosis. Methods for treating a patient in need thereof include administering an oral pharmaceutical formulation of Compound 1 to the patient.
    Type: Application
    Filed: July 31, 2018
    Publication date: March 7, 2019
    Applicant: Vertex Pharmaceuticals Incorporated
    Inventors: Marinus Jacobus VERWIJS, Rossitza Gueorguieva ALARGOVA, Ritu Rohit KAUSHIK, Irina Nikolaevna KADIYALA, Christopher YOUNG
  • Patent number: 10183927
    Abstract: The present invention provides crystalline forms of a compound of formula (I): Also provided are pharmaceutical compositions that include the provided crystalline forms and methods of using the provided crystalline forms and pharmaceutical compositions for the treatment of cancer.
    Type: Grant
    Filed: May 17, 2017
    Date of Patent: January 22, 2019
    Assignees: Biomed Valley Discoveries, Inc., Vertex Pharmaceuticals Incorporated
    Inventors: Gary DeCrescenzo, Dean Welsch, Petinka I. Vlahova, Stephan X. M. Boerrigter, Alexander Aronov, Ali Keshavarz-Shokri, Alexander N. Scangas, Kathy Stavropoulos, Benjamin Littler, Irina Nikolaevna Kadiyala, Rossitza Gueorguieva Alargova
  • Publication number: 20180325897
    Abstract: The present invention relates to compositions and co-crystals each comprising a compound of formula I having the structure: wherein each of R1 and R2 is H or 2H and a co-crystal former selected from adipic acid, citric acid, fumaric acid, maleic acid, succinic acid, or benzoic acid. Also within the scope of this invention are methods of making and using the same.
    Type: Application
    Filed: July 18, 2018
    Publication date: November 15, 2018
    Inventors: Kwame Wiredu Nti-Addae, Simon Adam O'Neil, Yuegang Zhang, Michael Waldo, Praveen Mudunuri, Bin Song, John Gregg Van Alsten, Mark Strohmeier, Kathy Stavropoulos, Irina Nikolaevna Kadiyala, Mettachit Navamal
  • Patent number: 10076513
    Abstract: A pharmaceutical composition comprising Compound 1, (3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid), and at least one excipient selected from: a filler, a diluent, a disintegrant, a surfactant, a binder, a glidant and a lubricant, the composition being suitable for oral administration to a patient in need thereof to treat a CFTR mediated disease such as Cystic Fibrosis. Methods for treating a patient in need thereof include administering an oral pharmaceutical formulation of Compound 1 to the patient.
    Type: Grant
    Filed: January 19, 2016
    Date of Patent: September 18, 2018
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Marinus Jacobus Verwijs, Rossitza Gueorguieva Alargova, Ritu Rohit Kaushik, Irina Nikolaevna Kadiyala, Christopher Young
  • Patent number: 10058546
    Abstract: A pharmaceutical composition comprising Compound 1, (R)-1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide, and at least one excipient selected from: a filler, a disintegrant, a surfactant, a glidant and a lubricant, the composition being suitable for oral administration to a patient in need thereof to treat a CFTR mediated disease such as Cystic Fibrosis. Methods for treating a patient in need thereof include administering the pharmaceutical composition of Compound 1 are also disclosed.
    Type: Grant
    Filed: November 3, 2016
    Date of Patent: August 28, 2018
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Rossitza Gueorguieva Alargova, Craig Antony Dunbar, Irina Nikolaevna Kadiyala
  • Patent number: 10039761
    Abstract: The present invention relates to compositions and co-crystals each comprising a compound of formula I having the structure: wherein each of R1 and R2 is H or 2H and a co-crystal former selected from adipic acid, citric acid, fumaric acid, maleic acid, succinic acid, or benzoic acid. Also within the scope of this invention are methods of making and using the same.
    Type: Grant
    Filed: April 15, 2016
    Date of Patent: August 7, 2018
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Kwame Wiredu Nti-Addae, Simon Adam O'Neil, Yuegang Zhang, Michael Waldo, Praveen Mudunuri, Bin Song, John Gregg Van Alsten, Mark Strohmeier, Kathy Stavropoulos, Irina Nikolaevna Kadiyala, Mettachit Navamal
  • Publication number: 20170320851
    Abstract: The present invention provides crystalline forms of a compound of formula (I): Also provided are pharmaceutical compositions that include the provided crystalline forms and methods of using the provided crystalline forms and pharmaceutical compositions for the treatment of cancer.
    Type: Application
    Filed: May 17, 2017
    Publication date: November 9, 2017
    Inventors: Gary DeCrescenzo, Dean Welsch, Petinka I. Vlahova, Stephan X.M. Boerrigter, Alexander Aronov, Ali Keshavarz-Shokri, Alexander N. Scangas, Kathy Stavropoulos, Benjamin Littler, Irina Nikolaevna Kadiyala, Rossitza Gueorguieva Alargova
  • Publication number: 20170266176
    Abstract: A pharmaceutical composition comprising Compound 1, (R)-1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide, and at least one excipient selected from: a filler, a disintegrant, a surfactant, a glidant and a lubricant, the composition being suitable for oral administration to a patient in need thereof to treat a CFR mediated disease such as Cystic Fibrosis. Methods for treating a patient in need thereof include administering the pharmaceutical composition of Compound 1 are also disclosed.
    Type: Application
    Filed: November 3, 2016
    Publication date: September 21, 2017
    Applicant: Vertex Pharmaceuticals Incorporated
    Inventors: Rossitza Gueorguieva Alargova, Craig Antony Dunbar, Irina Nikolaevna Kadiyala
  • Patent number: 9676746
    Abstract: The present invention provides crystalline forms of a compound of formula (I): Also provided are pharmaceutical compositions that include the provided crystalline forms and methods of using the provided crystalline forms and pharmaceutical compositions for the treatment of cancer.
    Type: Grant
    Filed: January 29, 2016
    Date of Patent: June 13, 2017
    Assignees: BioMed Valley Discoveries, Inc., Vertex Pharmaceuticals Incorporated
    Inventors: Gary DeCrescenzo, Dean Welsch, Petinka I. Vlahova, Stephan X. M. Boerrigter, Alexander Aronov, Ali Keshavarz-Shokri, Alexander N. Scangas, Kathy Stavropoulos, Benjamin Littler, Irina Nikolaevna Kadiyala, Rossitza Gueorguieva Alargova
  • Publication number: 20160339024
    Abstract: The present invention relates to compositions and co-crystals each comprising a compound of formula I having the structure: wherein each of R1 and R2 is H or 2H and a co-crystal former selected from adipic acid, citric acid, fumaric acid, maleic acid, succinic acid, or benzoic acid. Also within the scope of this invention are methods of making and using the same.
    Type: Application
    Filed: April 15, 2016
    Publication date: November 24, 2016
    Applicant: Vertex Pharmaceuticals Incorporated
    Inventors: Kwame Wiredu Nti-Addae, Simon Adam O'Neil, Yuegang Zhang, Michael Waldo, Praveen Mudunuri, Bin Song, John Gregg Van Alsten, Mark Strohmeier, Kathy Stavropoulos, Irina Nikolaevna Kadiyala, Mettachit Navamal
  • Publication number: 20160303096
    Abstract: A pharmaceutical composition comprising Compound 1, (3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid), and at least one excipient selected from: a filler, a diluent, a disintegrant, a surfactant, a binder, a glidant and a lubricant, the composition being suitable for oral administration to a patient in need thereof to treat a CFTR mediated disease such as Cystic Fibrosis. Methods for treating a patient in need thereof include administering an oral pharmaceutical formulation of Compound 1 to the patient.
    Type: Application
    Filed: January 19, 2016
    Publication date: October 20, 2016
    Applicant: VERTEX PHARMACEUTICALS INCORPORATED
    Inventors: MARINUS JACOBUS VERWIJS, ROSSITZA GUEORGUIEVA ALARGOVA, RITU ROHIT KAUSHIK, IRINA NIKOLAEVNA KADIYALA, CHRISTOPHER YOUNG